Menu Search
Equities

Novo Nordisk A/S

NOVO B:CPH

Novo Nordisk A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)993.50
  • Today's Change-11.10 / -1.10%
  • Shares traded2.91m
  • 1 Year change+80.73%
  • Beta0.7373
Data delayed at least 15 minutes, as of Jul 02 2024 16:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Jul-23
  • 18-Apr-24
  • 16-May-24
  • 20-Jun-24
  • 27-Jun-24
Select bar for recommendation details.
Recommendations27-Jun-24
Buy5
Outperform13
Hold9
Underperform0
Sell2

Share price forecast in DKK

The 26 analysts offering 12 month price targets for Novo Nordisk A/S have a median target of 995.00, with a high estimate of 1,200.00 and a low estimate of 530.00. The median estimate represents a -0.96% decrease from the last price of 1,004.60.
High19.5%1,200.00
Med-1.0%995.00
Low-47.2%530.00

Dividends in DKK

In 2023, Novo Nordisk A/S reported a dividend of 9.40 DKK, which represents a 51.61% increase over last year. The 23 analysts covering the company expect dividends of 11.41 DKK for the upcoming fiscal year, an increase of 21.38%.
Div growth (TTM)51.61%
More ▼

Earnings history & estimates in DKK

On May 02, 2024, Novo Nordisk A/S reported 1st quarter 2024 earnings of 5.68 per share. This result exceeded the 5.23 consensus of the 9 analysts covering the company and exceeded last year's 1st quarter results by 29.38%.
The next earnings announcement is expected on Aug 07, 2024.
Average growth rate+7.01%
Novo Nordisk A/S reported annual 2023 earnings of 18.62 per share on Jan 31, 2024.
Average growth rate+23.83%
More ▼

Revenue history & estimates in DKK

Novo Nordisk A/S had 1st quarter 2024 revenues of 65.35bn. This bettered the 63.21bn consensus of the 10 analysts covering the company. This was 22.45% above the prior year's 1st quarter results.
Average growth rate+5.32%
Novo Nordisk A/S had revenues for the full year 2023 of 232.26bn. This was 31.26% above the prior year's results.
Average growth rate+17.97%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.